Top

Published in:

01-05-2018 | Original Article

Evaluation of the effects of curcumin in patients with metabolic syndrome

Authors: Maryam Saberi-Karimian, Seyed Mohammad Reza Parizadeh, Majid Ghayour-Mobarhan, Malihe Moammeri Salahshooh, Behdokht Fathi Dizaji, Hamideh Safarian, Ali Javandoost, Gordon A. Ferns, Amirhosein Sahebkar, Malihe Ahmadinejad

Published in: Comparative Clinical Pathology | Issue 3/2018

Abstract

Curcumin is a yellow pigment derived from rhizomes of turmeric (Curcuma longa L.) and can affect multiple components metabolic syndrome (MetS). In the current study, we aimed to evaluate the effects of curcumin on several CVD risk factors, including indices of depression and anxiety in individuals with MetS. This randomized clinical trial was undertaken in the Nutrition Clinic of the Ghaem Hospital. One hundred and twenty subjects (18–65 years old) were randomly assigned to one of three treatment groups: a group receiving phospholipidated curcumin (PC) capsules (1 g/day) for 6 weeks )n = 40), a group receiving unformulated curcumin (UC) capsules (1 g/day) for 6 weeks (n = 40), and a control group who received a placebo capsule (n = 40). Socio-demographic status of all participants was documented using a self-administered questionnaire. Blood samples were collected after a 12-h fasting. All biochemical factors and anthropometric indices were measured in all patients at baseline and after 6 weeks intervention. Complete blood count (CBC), serum levels of FBG, lipid profile, apolipoproteins, and hs-CRP were assessed. Physical activity level was measured using a standard questionnaire. At the beginning and end of study, Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI) were completed by all volunteers. According to the self-reported adverse effects, one subject in the PC-treated group reported hypersensitivity. Also, there were reports of cold sore (n = 1) and nausea (n = 1) in the UC group. Statistical analyses were performed using SPSS software. A total of 109 subjects completed the study. There were no significant differences between the three study groups for any of the variables at baseline, nor after the 6 weeks intervention, including anthropometric indices, serum biochemical factors, systolic and diastolic blood pressures, and CBC. However, subjects with severe anxiety appeared to be significantly improved by treatment with the PC and UC compared with the placebo group (p = 0.01). Curcumin supplementation did not improve any of the cardiovascular risk factors associated with MetS.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818. https://doi.org/10.1021/mp700113r CrossRefPubMed

Basile V, Ferrari E, Lazzari S, Belluti S, Pignedoli F, Imbriano C (2009) Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol 78(10):1305–1315. https://doi.org/10.1016/j.bcp.2009.06.105 CrossRefPubMed

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4(6):561–571. https://doi.org/10.1001/archpsyc.1961.01710120031004 CrossRefPubMed

Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56(6):893–897. https://doi.org/10.1037/0022-006X.56.6.893 CrossRefPubMed

Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G (2010) Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 15(4):337–344PubMed

Bishnoi M, Chopra K, Rongzhu L, Kulkarni SK (2011) Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence. Neurotox Res 20(3):215–225. https://doi.org/10.1007/s12640-010-9229-4 CrossRefPubMed

Cuomo J, Appendino G, Dern AS, Schneider E, Mckinnon TP, Brown MJ, Togni S, Dixon BM (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74(4):664–669. https://doi.org/10.1021/np1007262 CrossRefPubMed

Den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salome PL, Rutten GE (2012) High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol 11(1):25. https://doi.org/10.1186/1475-2840-11-25 CrossRef

Di Pierro F, Bressan A, Ranaldi D, Rapacioli G, Giacomelli L, Bertuccioli A (2015) Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. Eur Rev Med Pharmacol Sci 19(21):4195–4202PubMed

Dunbar JA, Reddy P, Davis-Lameloise N, Philpot B, Laatikainen T, Kilkkinen A, Bunker SJ, Best JD, Vartiainen E, Kai Lo S, Janus ED (2008) Depression: an important comorbidity with metabolic syndrome in a general population. Diabetes Care 31(12):2368–2373. https://doi.org/10.2337/dc08-0175 CrossRefPubMedPubMedCentral

Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415e1428CrossRef

Epstein J, Sanderson IR, Macdonald TT (2010) Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103(11):1545–1557. https://doi.org/10.1017/S0007114509993667 CrossRefPubMed

Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F (2006) High prevalence of the metabolic syndrome in Iranian adolescents. Obesity 14(3):377–382. https://doi.org/10.1038/oby.2006.50 CrossRefPubMed

Fakhrzadeh H, Ebrahimpour P, Pourebrahim R, Heshmat R, Larijani B (2006) Metabolic syndrome and its associated risk factors in healthy adults: a population based study in Iran. Metab Syndr Relat Disord 4(1):28–34. https://doi.org/10.1089/met.2006.4.28 CrossRefPubMed

Garcia-Toro M, Vicens-Pons E, Gili M, Roca M, Serrano-Ripoll MJ, Vives M et al (2016) Obesity, metabolic syndrome and Mediterranean diet: impact on depression outcome. J Affect Disord 194:105–108. https://doi.org/10.1016/j.jad.2015.12.064 CrossRefPubMed

Grundy SM, Hansen B, Smith SC Jr et al (2004) Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109:551e556

Huffman FG, Gomez GP, Zarini GG (2009) Metabolic syndrome and high-sensitivity C-reactive protein in Cubans. Ethn Dis 19(2):115–120PubMed

James WPT, Schofield EC (1990) Organizacio’n de las Naciones Unidas para la Agricultura. Human energy requirements: a manual for planners and nutritionists. FAO and Oxford Medical Publications, New York

Jurenka JS (2009) Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14(2):141–153PubMed

Karalis DG (2008) The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes. Clin Cardiol 31(6):241–248. https://doi.org/10.1002/clc.20226 CrossRefPubMed

Kaur G, C M (2012) Amelioration of obesity, glucose intolerance, and oxidative stress in high-fat diet and low-dose streptozotocin-induced diabetic rats by combination consisting of “curcumin with piperine and quercetin”. ISRN Pharmacol 2012:957283. https://doi.org/10.5402/2012/957283 CrossRefPubMedPubMedCentral

Kulkarni SK, Bhutani MK, Bishnoi M (2008) Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology 201(3):435–442. https://doi.org/10.1007/s00213-008-1300-y CrossRefPubMed

Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI et al (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6(1):10. https://doi.org/10.1186/1472-6882-6-10 CrossRefPubMedPubMedCentral

Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD (2014) Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord 167:368–375. https://doi.org/10.1016/j.jad.2014.06.001 CrossRefPubMed

Marczylo TH, Verschoyle RD, Cooke DN et al (2007) Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60:171–177CrossRefPubMed

Mattson MP (2008) Hormesis defined. Ageing Res Rev 7(1):1–7. https://doi.org/10.1016/j.arr.2007.08.007 CrossRefPubMed

Mirhosseini N-Z, Yusoff NA, Shahar S, Parizadeh SMR, Mobarhen MG, Shakery MT (2009) Prevalence of the metabolic syndrome and its influencing factors among adolescent girls in Mashhad, Iran. Asia Pac J Clin Nutr 18(1):131–136PubMed

Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA (2013) Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27(3):374–379. https://doi.org/10.1002/ptr.4715 CrossRefPubMed

Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, Hu FB (2012) Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35(5):1171–1180. https://doi.org/10.2337/dc11-2055 CrossRefPubMedPubMedCentral

Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A (2014a) Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22(5):851–857. https://doi.org/10.1016/j.ctim.2014.07.006 CrossRefPubMed

Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A (2014b) Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 28(11):1625–1631. https://doi.org/10.1002/ptr.5174 CrossRefPubMed

Panahi Y, Badeli R, Karami GR, Sahebkar A (2015a) Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 29(1):17–21. https://doi.org/10.1002/ptr.5211 CrossRefPubMed

Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A (2015b) Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res 65(11):567–573. https://doi.org/10.1055/s-0034-1389986

Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A (2015c) Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr (Edinburgh, Scotland) 34(6):1101–1108. https://doi.org/10.1016/j.clnu.2014.12.019 CrossRef

Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, Akhlaghi S, Ferns GAA, Ghayour-Mobarhan M (2013) Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27(12):1883–1888. https://doi.org/10.1002/ptr.4952 CrossRefPubMed

Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B et al (2014) Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 28(4):579–585CrossRefPubMed

Scapagnini G, Colombrita C, Amadio M, D’Agata V et al (2006) Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid Redox Signal 8(3-4):395–403. https://doi.org/10.1089/ars.2006.8.395 CrossRefPubMed

Sekita A, Arima H, Ninomiya T, Ohara T, Doi Y, Hirakawa Y, Fukuhara M, Hata J, Yonemoto K, Ga Y, Kitazono T, Kanba S, Kiyohara Y (2013) Elevated depressive symptoms in metabolic syndrome in a general population of Japanese men: a cross-sectional study. BMC Public Health 13(1):862. https://doi.org/10.1186/1471-2458-13-862 CrossRefPubMedPubMedCentral

Semalty A, Semalty M, Rawat MS, Franceschi F (2010) Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals. Fitoterapia 81(5):306–314. https://doi.org/10.1016/j.fitote.2009.11.001 CrossRefPubMed

Shureiqi I, Baron JA (2011) Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila) 4(3):296–298. https://doi.org/10.1158/1940-6207.CAPR-11-0060 CrossRef

Strimpakos AS, Sharma RA (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10(3):511–545. https://doi.org/10.1089/ars.2007.1769 CrossRefPubMed

Vasconcellos MT, Anjos LA (2003) A simplified method for assessing physical activity level values for a country or study population. Eur J Clin Nutr 57(8):1025–1033. https://doi.org/10.1038/sj.ejcn.1601638 CrossRefPubMed

Villegas I, Sanchez-Fidalgo S, Alarcon de la Lastra C (2008) New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 52(9):1040–1061. https://doi.org/10.1002/mnfr.200700280 CrossRefPubMed

Visioli F, Davalos A (2011) Polyphenols and cardiovascular disease: a critical summary of the evidence. Mini Rev Med Chem 11(14):1186–1190PubMed

Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ (2005) The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 518(1):40–46. https://doi.org/10.1016/j.ejphar.2005.06.002 CrossRefPubMed

Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC (2014) Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res 28(12):1770–1777. https://doi.org/10.1002/ptr.5197 CrossRefPubMed

Yu ZF, Kong LD, Chen Y (2002) Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 83(1–2):161–165. https://doi.org/10.1016/S0378-8741(02)00211-8 CrossRefPubMed

Title: Evaluation of the effects of curcumin in patients with metabolic syndrome
Authors: Maryam Saberi-Karimian
Seyed Mohammad Reza Parizadeh
Majid Ghayour-Mobarhan
Malihe Moammeri Salahshooh
Behdokht Fathi Dizaji
Hamideh Safarian
Ali Javandoost
Gordon A. Ferns
Amirhosein Sahebkar
Malihe Ahmadinejad
Publication date: 01-05-2018
Publisher: Springer London
Published in: Comparative Clinical Pathology / Issue 3/2018
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-017-2624-y

At a glance: The STEP trials

Springer Medicine

Evaluation of the effects of curcumin in patients with metabolic syndrome

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Effects of temperature, pH, and bile salt on antimicrobial activity of bacteriocin-like substances obtained from barley sourdough LAB

Long-term effects of thyroxine-induced hyperthyroidism on the histological attributes of the oviduct in broiler breeder hens

Dramatic shortening of the diagnosis of multidrug-resistant tuberculosis by the detection of rifampicin resistance using a genotypic method: GeneXpert MTB/RIF assay

Growth performances, survival rate, and biochemical parameters of Nile tilapia (Oreochromis niloticus) reared in water treated with probiotic

Effect of traumatic reticulitis and allied syndromes on blood constituents in buffaloes

Is vitamin D supplement accompanied with narrow band UVB effective for treatment of vitiligo?